

\$%ASTN;HighlightOn= ***;HighlightOff=*** ;

Connecting via winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1635KXH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded
NEWS 5 SEP 29 DISSABS now available on STN
NEWS 6 OCT 10 PCTFULL: Two new display fields added
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9 NOV 24 MSDS-CCOHS file reloaded
NEWS 10 DEC 08 CABA reloaded with left truncation
NEWS 11 DEC 08 IMS file names changed
NEWS 12 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 14 DEC 17 DGENE: Two new display fields added
NEWS 15 DEC 18 BIOTECHNO no longer updated
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer
available
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS
databases
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19 DEC 22 ABI-INFORM now available on STN
NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 22 FEB 05 German (DE) application and patent publication number format
changes
NEWS 23 MAR 03 MEDLINE and LMEADLINE reloaded
NEWS 24 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 25 MAR 03 FRANCEPAT now available on STN

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS world wide web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:52:19 ON 03 MAR 2004

=> edline caplus lifesci embase uspatfull biosis

EDLINE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

=> b medline caplus lifesci embase uspatfull biosis
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 10:52:40 ON 03 MAR 2004

FILE 'CAPLUS' ENTERED AT 10:52:40 ON 03 MAR 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 10:52:40 ON 03 MAR 2004
 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 10:52:40 ON 03 MAR 2004
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:52:40 ON 03 MAR 2004
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:52:40 ON 03 MAR 2004
 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s (glutamic acid decarboxylase) and antisense and parkinson?
 L1 60 (GLUTAMIC ACID DECARBOXYLASE) AND ANTISENSE AND PARKINSON?

=> dup rem l1
 PROCESSING COMPLETED FOR L1
 L2 58 DUP REM L1 (2 DUPLICATES REMOVED)

=> d l2 ibib abs tot

L2 ANSWER 1 OF 58 USPATFULL on STN
 ACCESSION NUMBER: 2004:44499 USPATFULL
 TITLE: Proteins and nucleic acids encoding same
 INVENTOR(S): Alsobrook, John P., II, Madison, CT, UNITED STATES
 Anderson, David W., Branford, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Colman, Steven D., Guilford, CT, UNITED STATES
 Edinger, Shlomit R., New Haven, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Gerlach, Valerie, Branford, CT, UNITED STATES
 Gorman, Linda, Branford, CT, UNITED STATES
 Grosse, William M., Branford, CT, UNITED STATES
 Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
 Herrmann, John L., Guilford, CT, UNITED STATES
 Kekuda, Ramesh, Danbury, CT, UNITED STATES
 Lepley, Denise M., Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 MacDougall, John R., Hamden, CT, UNITED STATES
 Millet, Isabelle, Milford, CT, UNITED STATES
 Pena, Carol E. A., New Haven, CT, UNITED STATES
 Peyman, John A., New Haven, CT, UNITED STATES
 Rastelli, Luca, Guilford, CT, UNITED STATES
 Rieger, Daniel K., Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Smithson, Glenda, Guilford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Stone, David J., Guilford, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Vernet, Corine A.M., Branford, CT, UNITED STATES
 Voss, Edward Z., Wallingford, CT, UNITED STATES
 Zerhusen, Bryan D., Branford, CT, UNITED STATES
 Zhong, Haihong, Guilford, CT, UNITED STATES
 Zhong, Mei, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033491	A1	20040219
APPLICATION INFO.:	US 2001-16248	A1	20011210 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2000-254329P 20001208 (60)
US 2001-291037P 20010515 (60)
US 2000-255648P 20001214 (60)
US 2001-297173P 20010608 (60)
US 2001-309258P 20010731 (60)
US 2001-326393P 20011001 (60)
US 2001-315639P 20010829 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY
and POPEO, P.C., One Financial Center, Boston, MA,
02111

NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 12259

AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L2 ANSWER 2 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:13072 USPATFULL
TITLE: Genetically-modified neural progenitors and uses thereof
INVENTOR(S): Sabate, Olivier, Paris, FRANCE
Horellou, Philippe, Paris, FRANCE
Buc-Caron, Marie-Helene, Paris, FRANCE
Mallet, Jacques, Paris, FRANCE
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009592	A1	20040115
APPLICATION INFO.:	US 2002-305386	A1	20021127 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-810315, filed on 28 Feb 1997, ABANDONED		

	NUMBER	DATE
PATENT INFORMATION:	US 1996-12635P	19960301 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1050	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention concerns human neural progenitor cells containing introduced genetic material encoding a product of interest, and their use for the treatment of neurodegenerative diseases.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2004:7469 USPATFULL
TITLE: Low oxygen culturing of central nervous system progenitor cells
INVENTOR(S): Csete, Marie, Ann Arbor, MI, UNITED STATES
Doyle, John, South Pasadena, CA, UNITED STATES
Wold, Barbara J., San Marino, CA, UNITED STATES
McKay, Ron, Bethesda, MD, UNITED STATES
Studer, Lorenz, New York, NY, UNITED STATES
PATENT ASSIGNEE(S): California Institute of Technology (U.S. corporation)
National Institutes of Health (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005704	A1	20040108
APPLICATION INFO.:	US 2003-462896	A1	20030613 (10)

1999, GRANTED, Pat. No. US 6610540 Continuation-in-part
of Ser. No. US 1998-195569, filed on 18 Nov 1998,
GRANTED, Pat. No. US 6184035

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: K. Shannon Mrksich, BRINKS HOFER GILSON & LIONE, P.O.
BOX 10395, CHICAGO, IL, 60610

NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the growth of cells in culture under conditions that promote cell survival, proliferation, and/or cellular differentiation. The present inventors have found that proliferation was promoted and apoptosis reduced when cells were grown in lowered oxygen as compared to environmental oxygen conditions traditionally employed in cell culture techniques. Further, the inventors found that differentiation of precursor cells to specific fates also was enhanced in lowered oxygen where a much greater number and fraction of dopaminergic neurons were obtained when mesencephalic precursors were expanded and differentiated in lowered oxygen conditions. Thus at more physiological oxygen levels the proliferation and differentiation of CNS precursors is enhanced, and lowered oxygen is a useful adjunct for ex vivo generation of specific neuron types. Methods and compositions exploiting these findings are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2004:7342 USPATFULL
TITLE: Proteins and nucleic acids encoding same
INVENTOR(S): Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A., North Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Edinger, Schlomit, New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010820 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C.,

NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 17887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2004:7326 USPATFULL
TITLE: Markers of neuronal differentiation and morphogenesis
INVENTOR(S): Loring, Jeanne F., Foster City, CA, UNITED STATES
Kaser, Matthew R., Castro Valley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005559	A1	20040108
APPLICATION INFO.:	US 2002-62674	A1	20020130 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-625102, filed on 24 Jul 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5725		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cDNAs that are diagnostic of and participate in neuronal differentiation and morphogenesis, proteins encoded by the cDNAs and agonists, antagonists, and antibodies that specifically bind the protein. The invention also provides compositions containing cDNAs, proteins, or antibodies and methods for their use diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:283103 USPATFULL
TITLE: Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
INVENTOR(S): Goldman, Steven A., South Salem, NY, UNITED STATES
Chmielnicki, Eva, New York, NY, UNITED STATES
Economides, Aris, Tarrytown, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199447	A1	20031023
APPLICATION INFO.:	US 2003-368809	A1	20030214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358005P	20020215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael L. Goldman, NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603-1051	
NUMBER OF CLAIMS:	106	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1728	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of inducing neuronal production in a subject, a method of recruiting neurons to a subject's brain, and a method of treating a neurodegenerative condition by administering a neurotrophic factor and an inhibitor of pro-gliogenic bone morphogenetic proteins. Also disclosed is a method of suppressing astrocyte generation and inducing neuronal production in a subject, a method of treating a neurologic condition, and a method of suppressing glial scar formation in a subject by administering an inhibitor of

invention involves a method of introducing a heterogeneous protein into a subject's brain and spinal cord by introducing a nucleic acid molecule encoding the heterogeneous protein introduced into the subject's ependyma, permitting the protein from the nucleic acid molecule to be expressed within the subject's ependyma, and permitting the expressed protein to migrate within the subject's brain and spinal cord.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:265269 USPATFULL
 TITLE: Method of screening ptp .cedilla. activitiy promoter or inhibitor
 INVENTOR(S): Noda, Masaharu, Aichi, JAPAN
 Fujikawa, Akihiro, Aichi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186284	A1	20031002
APPLICATION INFO.:	US 2003-333786	A1	20030124 (10)
	WO 2001-JP6343		20010723

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-223184	20000724
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	1319	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An object of the present invention is to provide a remedy for dysfunction of central monoamine pathway, a method for screening a PTP.zeta. inhibitor or activator, which is useful as a remedy for gastric ulcer caused by Helicobacter pylori or pleiotrophin which is a heparin-binding secretory protein, and a non-human model animal being hyposensitive to a stimulant drug, vacA which is a toxin of Helicobacter pylori, or pleiotrophin by utilizing the physiological function of PTP.zeta.. After administering a subject material to PTP.zeta. knockout mice and wild-type mice, PTP.zeta. activity in the PTP.zeta. knockout mice and the wild-type mice is compared and evaluated to screen a PTP.zeta. inhibitor or activator. Examples of the comparison and the evaluation of the PTP.zeta. activity include the comparison and the evaluation of the function of central monoamine pathway such as changes in the level of central monoamine metabolism, sensitivity to a stimulant drug, the presence of dysfunction of mesolimbic dopamine pathway, level of acclimation to new circumstances, or stress-responsiveness, and the comparison and the evaluation of the level of binding to vacA, a toxin of Helicobacter pylori, or pleiotrophin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:251172 USPATFULL
 TITLE: Methods for using bag expression as a cell differentiation agent and marker
 INVENTOR(S): Reed, John C., Rancho Santa Fe, CA, UNITED STATES
 Kermer, Pawel, San Diego, CA, UNITED STATES
 Krajewski, Stanislaw, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175958	A1	20030918
APPLICATION INFO.:	US 2002-99553	A1	20020315 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PERKINS COIE LLP, 101 Jefferson Drive, Menlo Park, CA, 94025-1114		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	1817		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

which involves modifying a cell to increase expression of a BAG polypeptide that promotes differentiation of a cell, such as a neuronal cell, stem cell or neural progenitor cell. The invention provides another method for promoting cell differentiation, which involves modifying a cell to increase the amount of a nuclear localized BAG polypeptide, when the nuclear localized BAG polypeptide promotes differentiation of the cell. The invention also provides methods for reducing the rate of cell proliferation and suppressing apoptosis. The methods involve modifying a cell to increase the amount of a nuclear localized BAG polypeptide, when the nuclear localized BAG polypeptide inhibits proliferation, or suppresses apoptosis, respectively.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:225262 USPATFULL
 TITLE: Methods for pretreating a subject with apoptotic cells
 INVENTOR(S): Peritt, David L., Bala Cynwyd, PA, UNITED STATES
 Harriman, Gregory, Paoli, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157073	A1	20030821
APPLICATION INFO.:	US 2002-306786	A1	20021129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333746P	20011129 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103	
NUMBER OF CLAIMS:	212	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6889	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention also relates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:213275 USPATFULL
 TITLE: Adeno-associated virus materials and methods
 INVENTOR(S): Johnson, Philip R., Columbus, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003147912	A1	20030807
APPLICATION INFO.:	US 2003-375777	A1	20030226 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-163886, filed on 4 Jun 2002, ABANDONED Continuation of Ser. No. US 2002-77294, filed on 15 Feb 2002, ABANDONED Continuation of Ser. No. US 2000-691604, filed on 18 Oct 2000, PENDING Continuation of Ser. No. US 1999-292703, filed on 15 Apr 1999, ABANDONED Continuation of Ser. No. US 1998-12132, filed on 22 Jan 1998, ABANDONED Continuation of Ser. No. US 1995-466606, filed on 6 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-254358, filed on 6 Jun 1994, GRANTED, Pat. No. US 5658785		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357		
NUMBER OF CLAIMS:	25		

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 1013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:201479 USPATFULL

TITLE: Methods for pretreating a subject with extracorporeal photopheresis

INVENTOR(S): Peritt, David L., Bala Cynwyd, PA, UNITED STATES
Harriman, Gregory, Paoli, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003139466	A1	20030724
APPLICATION INFO.:	US 2002-306859	A1	20021129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333746P	20011129 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Dianne B. Elderkin, Esq., WOODCOCK WASHBURN LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103	
NUMBER OF CLAIMS:	112	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6681	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention also relates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:173922 USPATFULL

TITLE: Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors

INVENTOR(S): Lai, Zhennan, N. Potomac, MD, UNITED STATES
Reiser, Jakob, New Orleans, LA, UNITED STATES
Brady, Roscoe O., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119770	A1	20030626
APPLICATION INFO.:	US 2002-212634	A1	20020802 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-310012P	20010802 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to use of recombinant lentiviral vectors containing a therapeutic gene of interest fused in-frame with an intercellular trafficking gene for the global delivery of therapeutic proteins in nondividing cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:172722 USPATFULL

TITLE: Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof

INVENTOR(S): Neuman, Toomas, Santa Monica, CA, UNITED STATES
Levesque, Michel, Beverly Hills, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003118566	A1	20030626
APPLICATION INFO.:	US 2002-216677	A1	20020808 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-310727P	20010808 (60)
	US 2001-312714P	20010816 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614

NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1

LINE COUNT: 1836

AB The invention is directed to the field of human stem cells and includes methods and compositions for isolating, propagating, and differentiating human stem cells. The invention provides therapeutic uses of the methods and compositions, including autologous transplantation of treated cells into humans for treatment of ***Parkinson*** 's and other neuronal disorders.

L2 ANSWER 14 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:159395 USPATFULL

TITLE: Methods of making CDNA libraries

INVENTOR(S): Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109008	A1	20030612
APPLICATION INFO.:	US 2002-199830	A1	20020719 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-486313, filed on 7 Jun 1995, GRANTED, Pat. No. US 6497872 Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, ABANDONED Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation of Ser. No. US 1995-385404, filed on 7 Feb 1995, ABANDONED Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, ABANDONED Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, ABANDONED Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, ABANDONED		

on 8 Jul 1991, ABANDONED Continuation-in-part of Ser.
No. US 1994-338730, filed on 14 Nov 1994, ABANDONED
Continuation-in-part of Ser. No. US 1991-726812, filed
on 8 Jul 1991, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ LEVIN, One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 3873

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention discloses methods of proliferation and differentiation of multipotent neural stem cells. Also provided are methods of making cDNA libraries and methods of screening biological agents which affect proliferation differentiation survival phenotype or function of CNS cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:146370 USPATFULL
TITLE: Canine adenovirus vectors for the transfer of genes in targeted cells
INVENTOR(S): Kremer, Eric, Castelnau le Lez, FRANCE
Chillon Rodriguez, Miguel, Barcelone, SPAIN
Soudais, Claire, Fontenay Aux Roses, FRANCE
Boutin, Sylvie, Alfortville, FRANCE
Peltekian, Elise, Paris, FRANCE
Garcia, Luis, Saint Denis, FRANCE
Vincent, Nathalie, Saintry Sur Seine, FRANCE
Danos, Olivier, Fontainebleau, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003100116	A1	20030529
APPLICATION INFO.:	US 2002-165202	A1	20020607 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP12792, filed on 6 Dec 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-403061	19991207
	EP 1999-403078	19991208
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	42 Drawing Page(s)	
LINE COUNT:	1980	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant Canine Adenovirus (CAV) vectors based on CAV-2 strain Toronto in which the CAV-2 E1 region has been deleted are described herein. Methods for the preparation of recombinant vectors include the use of transcomplementation cell lines which are specifically employed to reduce the likelihood of generating replication competent CAV-2 during propagation of the vectors. The resultant replication-defective, E1-deficient CAV preparations are highly desirable for the transfer of nucleic acid sequences in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:140116 USPATFULL
TITLE: Methods of proliferating undifferentiated neural cells
INVENTOR(S): weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003095956	A1	20030522
APPLICATION INFO.:	US 2002-199918	A1	20020719 (10)

1995, PENDING Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, ABANDONED
 Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, ABANDONED
 Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
 Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, ABANDONED
 Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
 Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
 Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
 Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
 Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Ivor R. Elrifi, Esquire, One Financial Center, Boston, MA, 02111
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Page(s)
 LINE COUNT: 3838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention discloses methods of proliferation and differentiation of multipotent neural stem cells. Also provided are methods of making cDNA libraries and methods of screening biological agents which affect proliferation differentiation survival phenotype or function of CNS cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 58 USPATFULL on STN
 ACCESSION NUMBER: 2003:127052 USPATFULL
 TITLE: Transcriptional regulation of target genes
 INVENTOR(S): Kaplitt, Michael G., New York, NY, UNITED STATES
 During, Matthew J., Philadelphia, PA, UNITED STATES
 Lozano, Andres M., Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087264	A1	20030508
APPLICATION INFO.:	US 2002-151702	A1	20020520 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292604P	20010521 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1123	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:120030 USPATFULL
TITLE: Methods of screening biological agents
INVENTOR(S): Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082515	A1	20030501
APPLICATION INFO.:	US 2002-199189	A1	20020719 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-486313, filed on 7 Jun 1995, PENDING Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, ABANDONED		
	Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation of Ser. No. US 1995-385404, filed on 7 Feb 1995, ABANDONED		
	Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED		
	Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, ABANDONED		
	Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED		
	Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, ABANDONED Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, ABANDONED		
	Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, ABANDONED		
	Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, ABANDONED		
	Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, ABANDONED		
	Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Ivor R. Elrifi Esquire, MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	3844		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention discloses methods of proliferation and differentiation of multipotent neural stem cells. Also provided are methods of making cDNA libraries and methods of screening biological agents which affect proliferation differentiation survival phenotype or function of CNS cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:119660 USPATFULL
TITLE: Adeno-associated virus materials and methods
INVENTOR(S): Johnson, Philip R., Columbus, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082145	A1	20030501
APPLICATION INFO.:	US 2002-263127	A1	20021002 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-77294, filed on 15 Feb 2002, PENDING Continuation of Ser. No. US 2000-691604, filed on 18 Oct 2000, PENDING Continuation of Ser. No. US 1999-292703, filed on 15 Apr 1999, ABANDONED		
	Continuation of Ser. No. US 1998-12132, filed on 22 Jan 1998, ABANDONED Continuation of Ser. No. US 1995-466606, filed on 6 Jun 1995, ABANDONED		
	Continuation-in-part of Ser. No. US 1994-254358, filed on 6 Jun 1994, GRANTED, Pat. No. US 5658785		

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH
WACKER, CHICAGO, IL, 60606-6357
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:86828 USPATFULL
TITLE: TREATMENT OF ***PARKINSON*** 'S DISEASE WITH OLIGONUCLEOTIDES
INVENTOR(S): SCHNEIDER, JAY S., CHERRY HILL, NJ, UNITED STATES
PATENT ASSIGNEE(S): CLIFFORD KENT WEBER ESQ. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060436	A1	20030327
APPLICATION INFO.:	US 1999-435249	A1	19991105 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-107191P	19981105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DRINKER BIDDLE & REATH, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treatment of ***Parkinson*** 's disease, and to the use of ***antisense*** oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the ***parkinsonian*** brain. ***Antisense*** or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata (SNr) where the expression of ***glutamic*** ***acid*** ***decarboxylase*** (GAD.sub.67, GAD.sub.65, or a combination of the two isoforms) is downregulated. The present invention also relates to a method of treatment of ***Parkinson*** 's disease where ***antisense*** or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The present invention further relates to a method of treatment of ***Parkinson*** 's disease where ***antisense*** or triplex oligonucleotides are targeted to the thalamic motor nuclei for the downregulation of GABA receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:71552 USPATFULL
TITLE: In vitro and in vivo proliferation and use of multipotent neural stem cells and their progeny
INVENTOR(S): Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hamman, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049837	A1	20030313
APPLICATION INFO.:	US 2001-925911	A1	20010809 (9)

1995, GRANTED, Pat. No. US 6399369 Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, ABANDONED Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation of Ser. No. US 1995-385404, filed on 7 Feb 1995, ABANDONED Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, ABANDONED Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, ABANDONED Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ LEVIN, One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 4025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids may be obtained from neural cell cultures produced by using growth factors to induce the proliferation of multipotent neural stem cells. The resultant progeny may be passaged repeatedly to produce a sufficient number of cells to obtain representative nucleic acid samples. Clonal cultures may be produced. Nucleic acids may be obtained from both cultured normal and dysfunctional neural cells and from neural cell cultures at various stages of development. This information allows for the identification of the sequence of gene expression during neural development and can be used to reveal the effects of biological agents on gene expression in neural cells. Additionally, nucleic acids derived from dysfunctional tissue can be compared with that of normal tissue to identify genetic material which may be the cause of the dysfunction. This information could then be used in the design of therapies to treat the neurological disorder. A further use of the technology would be in the diagnosis of genetic disorders or for use in identifying neural cells at a particular stage in development.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:70969 USPATFULL
TITLE: Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule
INVENTOR(S): Kaufman, Daniel L., Los Angeles, CA, UNITED STATES
Hanssen, Lorraine, Los Angeles, CA, UNITED STATES
Zekzer, Dan, Encinitas, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049254	A1	20030313
APPLICATION INFO.:	US 2002-161647	A1	20020605 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295596P	20010605 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sharon E. Crane, Ph.D., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404	
NUMBER OF CLAIMS:	66	

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 2511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods and compositions for treating neural damage caused by injury or disease, by enhancing neural outgrowth and/or repair responses in the nervous system. Preferably, the methods and compositions utilize agents which interfere with the ability of the major histocompatibility complex (MHC) Class I molecule (MHC I) to inhibit neurite outgrowth. Such agents include antibodies directed to MHC I, MHC I fragments and/or analogs, and agents which interfere with MHC I interaction with its neuronal receptor and the receptor's signaling pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:70918 USPATFULL

TITLE: Targeted nucleic acid constructs and uses related thereto

INVENTOR(S): Elmaleh, David R., Newton, MA, UNITED STATES
Fischman, Alan J., Boston, MA, UNITED STATES
Babich, John W., Scituate, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049203	A1	20030313
APPLICATION INFO.:	US 2001-945166	A1	20010831 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	2270		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides targeted constructs comprising a targeting moiety, a nucleic acid, and a payload. The payload can be a detectable label or a therapeutic agent. The nucleic acid can be an ***antisense*** molecule that is complementary to RNA present in a target cell. The targeted constructs can be used to introduce the payload into a target cell in vivo or in vitro. Accordingly, the invention can be used for diagnostic purposes and for therapeutic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 24 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:57546 USPATFULL

TITLE: Differentiated cells suitable for human therapy

INVENTOR(S): Gold, Joseph D., San Francisco, CA, UNITED STATES
Lebkowski, Jane S., Portola Valley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003040111	A1	20030227
APPLICATION INFO.:	US 2002-141220	A1	20020507 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-783203, filed on 13 Feb 2001, PENDING Continuation of Ser. No. WO 2001-US44309, filed on 26 Nov 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253443P	20001127 (60)
	US 2000-253357P	20001127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	3280	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell

control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 25 OF 58 USPATFULL on STN
 ACCESSION NUMBER: 2003:57516 USPATFULL
 TITLE: Bio-synthetic photostimulators and methods of use
 INVENTOR(S): Miesenbock, Gero, New York, NY, UNITED STATES
 Zemelman, Boris V., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003040080	A1	20030227
APPLICATION INFO.:	US 2002-222675	A1	20020816 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-345741P	20011231 (60)
	US 2001-312707P	20010816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	2021	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for rendering a cell sensitive to stimulation. In a preferred embodiment, the method comprises introducing, into a cell, nucleic acid sequences encoding at least an opsin gene product, an arrestin gene product, and the alpha subunit of the heterotrimeric G protein of the G.sub.q family. The introduced nucleic acid sequences are then expressed by the non-photoreceptor cell to yield at least the opsin gene product, the arrestin gene product, and the alpha subunit of the heterotrimeric G protein of the G.sub.q family. Retinal or a derivative thereof capable of bonding with the opsin gene product to form a rhodopsin is then provided to the non-photoreceptor cell. The non-photoreceptor cell is then irradiated with light having a wavelength capable of converting the rhodopsin to metarhodopsin. The conversion of rhodopsin to metarhodopsin triggers a cascade of intracellular responses within the cell resulting in an increased intracellular concentration of IP.sub.3 and calcium ions leading to an action potential in the cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 58 USPATFULL on STN
 ACCESSION NUMBER: 2003:44877 USPATFULL
 TITLE: Selective antibody targeting of undifferentiated stem cells
 INVENTOR(S): McWhir, Jim, Midlothian, UNITED KINGDOM
 Gold, Joseph D., San Francisco, CA, UNITED STATES
 Schiff, J. Michael, Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003032187	A1	20030213
APPLICATION INFO.:	US 2001-995419	A1	20011126 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253357P	20001127 (60)
	US 2000-253443P	20001127 (60)
	US 2000-253395P	20001127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

CA, 94025
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4177

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:44759 USPATFULL
TITLE: Evaluating neuropsychiatric diseases using a specimen-linked database
INVENTOR(S): Muraca, Patrick J., Pittsfield, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003032069	A1	20030213
APPLICATION INFO.:	US 2002-184671	A1	20020628 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302223P	20010629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, PAULA CAMPBELL EVANS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	75	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3380	

AB The invention relates to a method and system for identifying and evaluating the responses of a patient to a neuropsychiatric disorder. Preferably, both physiological and behavioral responses are linked to molecular profiling data, i.e., data relating to the expression of a plurality of genes in tissues from the patient with these diseases. In one aspect, the invention provides a tissue information system comprising a specimen-linked database and an information management system for accessing, organizing, and displaying tissue information obtained from tissue microarrays comprising samples from patients with neuropsychiatric disorders.

L2 ANSWER 28 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2003:3539 USPATFULL
TITLE: Multipotent stem cells from peripheral tissues and uses thereof
INVENTOR(S): Toma, Jean, Montreal, CANADA
Akhavan, Mahnaz, Montreal, CANADA
Fernandes, Karl J. L., Montreal, CANADA
Fortier, Mathieu, Orford, CANADA
Miller, Freda, Montreal, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003003574	A1	20030102
APPLICATION INFO.:	US 2002-99539	A1	20020315 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-991480, filed on 9 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-916639, filed on 26 Jul 2001, PENDING Continuation-in-part of Ser. No. WO 2001-CA47, filed on 24 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. US 2000-670049, filed on 25 Sep 2000, PENDING		

on 24 Jan 2000, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA,
02110-2624
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 2354

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 29 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:228269 USPATFULL
TITLE: Low oxygen culturing of central nervous system progenitor cells
INVENTOR(S): Csete, Marie, Ann Arbor, MI, United States
Doyle, John, South Pasadena, CA, United States
Wold, Barbara J., San Marino, CA, United States
McKay, Ron, Bethesda, MD, United States
Studer, Lorenz, New York, NY, United States
PATENT ASSIGNEE(S): California Institute of Technology, Pasadena, CA, United States (U.S. corporation)
National Institutes of Health, Bethesda, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6610540	B1	20030826
APPLICATION INFO.:	US 1999-425462		19991022 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-195569, filed on 18 Nov 1998, now patented, Pat. No. US 6184035		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
ASSISTANT EXAMINER:	Bunner, Bridget E.		
LEGAL REPRESENTATIVE:	Brinks Hofer Gilson & Lione		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2398		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the growth of cells in culture under conditions that promote cell survival, proliferation, and/or cellular differentiation. The present inventors have found that proliferation was promoted and apoptosis reduced when cells were grown in lowered oxygen as compared to environmental oxygen conditions traditionally employed in cell culture techniques. Further, the inventors found that differentiation of precursor cells to specific fates also was enhanced in lowered oxygen where a much greater number and fraction of dopaminergic neurons were obtained when mesencephalic precursors were expanded and differentiated in lowered oxygen conditions. Thus at more physiological oxygen levels the proliferation and differentiation of CNS precursors is enhanced, and lowered oxygen is a useful adjunct for ex vivo generation of specific neuron types. Methods and compositions exploiting these findings are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 30 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:6896 USPATFULL
TITLE: AAV-mediated delivery of DNA to cells of the nervous system
INVENTOR(S): Kaplitt, Michael G., New York, NY, United States
During, Matthew J., Weston, CT, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States (U.S. corporation)
Yale University, New Haven, CT, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6503888 B1 20030107
APPLICATION INFO.: US 2000-548176 20000413 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-467044, filed on 6 Jun 1995, now patented, Pat. No. US 6180613
Continuation-in-part of Ser. No. US 1994-227319, filed on 13 Apr 1994, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Martinell, James
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1762

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of delivering exogenous DNA to a target cell of the mammalian central nervous system using an adeno-associated virus (AAV)-derived vector. Also included in the invention are the AAV-derived vectors containing exogenous DNA which encodes a protein or proteins which prevent or treat nervous system disease, and a method of prevent or treating such disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 31 OF 58 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2003011859 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12518298
TITLE: Experimental ***parkinsonism*** is associated with increased pallidal GAD gene expression and is reversed by site-directed ***antisense*** gene therapy.
AUTHOR: Schneider Jay S; Wade Timothy V
CORPORATE SOURCE: Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.. jay.schneider@mail.tju.edu
SOURCE: Movement disorders : official journal of the Movement Disorder Society, (2003 Jan) 18 (1) 32-40.
Journal code: 8610688. ISSN: 0885-3185.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20030109
Last Updated on STN: 20030320
Entered Medline: 20030319

AB The levels of mRNA encoding the two isoforms of ***glutamic*** acid*** decarboxylase*** (GAD(65) and GAD(67)) were measured throughout the pallidal complex in normal and acutely (i.e., 1 month duration) and chronically (i.e., 5 years duration) ***parkinsonian*** 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) -treated monkeys as well as in monkeys exposed to MPTP but asymptomatic for ***parkinsonism***. GAD(65) mRNA labeling was modestly increased in the mid/caudal internal globus pallidus (GPi) but not in the external globus pallidus (GPe) in ***parkinsonian*** monkeys, compared with normal and asymptomatic monkeys. GAD(67) mRNA expression was highly increased in the mid/caudal GPi, and modestly increased in the GPe in ***parkinsonian*** monkeys compared with normal and asymptomatic animals. Infusion of GAD(67) ***antisense*** oligodeoxynucleotides bilaterally into the GPi resulted in a transient reversal of akinesia and bradykinesia that was not produced by infusion of missense oligodeoxynucleotides. These data emphasize the role of GAD enzyme (particularly GAD(67)) and GABA in the GPi for the expression of ***parkinsonian*** motor signs and suggest that selective manipulation of GABAergic neurotransmission in the GPi may have therapeutic potential for treating ***parkinsonism***.
Copyright 2002 Movement Disorder Society

L2 ANSWER 32 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:329450 USPATFULL
TITLE: Adeno-associated virus materials and methods
INVENTOR(S): Johnson, Philip R., Columbus, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002187129	A1	20021212
APPLICATION INFO.:	US 2002-163886	A1	20020604 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-77294, filed on 15 Feb		

filed on 18 Oct 2000, PENDING Continuation of Ser. No. US 1999-292703, filed on 15 Apr 1999, ABANDONED Continuation of Ser. No. US 1998-12132, filed on 22 Jan 1998, ABANDONED Continuation of Ser. No. US 1995-466606, filed on 6 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-254358, filed on 6 Jun 1994, GRANTED, Pat. No. US 5658785

DOCUMENT TYPE:
FILE SEGMENT:
LEGAL REPRESENTATIVE:

Utility
APPLICATION
Greta E. Noland, MARSHALL, GERSTEIN & BORUN, Sears Tower, 233 S. Wacker Drive, Suite 6300, Chicago, IL, 60606-6357

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 33 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:287120 USPATFULL
TITLE: Adeno-associated virus materials and methods
INVENTOR(S): Johnson, Philip R., Columbus, OH, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002159979	A1	20021031
APPLICATION INFO.:	US 2002-77294	A1	20020215 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-691604, filed on 18 Oct 2000, PENDING Continuation of Ser. No. US 1999-292703, filed on 15 Apr 1999, ABANDONED Continuation of Ser. No. US 1998-12132, filed on 22 Jan 1998, ABANDONED Continuation of Ser. No. US 1995-466606, filed on 6 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-254358, filed on 6 Jun 1994, GRANTED, Pat. No. US 5658785		

DOCUMENT TYPE:
FILE SEGMENT:
LEGAL REPRESENTATIVE:

Utility
APPLICATION
MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 34 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:227988 USPATFULL
TITLE: Multipotent stem cells from peripheral tissues and uses thereof
INVENTOR(S): Toma, Jean, Montreal, CANADA
Akhavan, Mahnaz, Montreal, CANADA
Fernandes, Karl J. L., Montreal, CANADA
Fortier, Mathieu, Orford, CANADA
Miller, Freda, Montreal, CANADA

PATENT INFORMATION: US 2002123143 A1 20020905
APPLICATION INFO.: US 2001-991480 A1 20011109 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-916639, filed
on 26 Jul 2001, PENDING Continuation-in-part of Ser.
No. WO 2001-CA47, filed on 24 Jan 2001, UNKNOWN
Continuation-in-part of Ser. No. US 2000-670049, filed
on 25 Sep 2000, PENDING Continuation-in-part of Ser.
No. US 2000-490422, filed on 24 Jan 2000, ABANDONED
Continuation-in-part of Ser. No. US 1997-920272, filed
on 22 Aug 1997, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA,
02110-2624

NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 2174

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to multipotent stem cells, purified from the
peripheral tissue of mammals, and capable of differentiating into neural
and non-neural cell types. These stem cells provide an accessible source
for autologous transplantation into CNS, PNS, and other damaged tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 35 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:185669 USPATFULL
TITLE: Differentiated stem cells suitable for human therapy
INVENTOR(S): Gold, Joseph D., San Francisco, CA, UNITED STATES
Lebkowski, Jane S., Portola Valley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098582	A1	20020725
	US 6576464	B2	20030610
APPLICATION INFO.:	US 2001-783203	A1	20010213 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253443P	20001127 (60)
	US 2000-253357P	20001127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	3087	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a system for producing differentiated cells from
a stem cell population for use wherever a relatively homogenous cell
population is desirable. The cells contain an effector gene under
control of a transcriptional control element (such as the TERT promoter)
that causes the gene to be expressed in relatively undifferentiated
cells in the population. Expression of the effector gene results in
depletion of undifferentiated cells, or expression of a marker that can
be used to remove them later. Suitable effector sequences encode a
toxin, a protein that induces apoptosis, a cell-surface antigen, or an
enzyme (such as thymidine kinase) that converts a prodrug into a
substance that is lethal to the cell. The differentiated cell
populations produced according to this disclosure are suitable for use
in tissue regeneration, and non-therapeutic applications such as drug
screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 36 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:92654 USPATFULL
TITLE: Method of inducing neuronal production in the brain and
spinal cord
INVENTOR(S): Goldman, Steven A., South Salem, NY, UNITED STATES
Benraiss, Abdellatif, Astoria, NY, UNITED STATES

PATENT INFORMATION: US 2002049178 A1 20020425
APPLICATION INFO.: US 2001-846588 A1 20010501 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201230P	20000501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael L. Goldman, Esq., NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603-1051
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 1997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of inducing neuronal production in the brain, recruiting neurons to the brain, and treating a neurodegenerative condition by providing a nucleic acid construct encoding a neurotrophic factor, and injecting the nucleic acid construct intraventricularly into a subject's brain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 37 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:27155 USPATFULL
TITLE: Multipotent neural stem cells from peripheral tissues and uses thereof
INVENTOR(S): Toma, Jean, Montreal, CANADA
Akhavan, Mahnaz, Montreal, CANADA
Fernandes, Karl J. L., Montreal, CANADA
Fortier, Mathieu, Orford, CANADA
Miller, Freda, Montreal, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002016002	A1	20020207
APPLICATION INFO.:	US 2001-916639	A1	20010726 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-CA47, filed on 24 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. US 2000-670049, filed on 25 Sep 2000, UNKNOWN Continuation-in-part of Ser. No. US 2000-490422, filed on 24 Jan 2000, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624		
NUMBER OF CLAIMS:	56		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Page(s)		
LINE COUNT:	1697		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to multipotent neural stem cells, purified from the peripheral nervous system of mammals, capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 38 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:12280 USPATFULL
TITLE: GENETICALLY-MODIFIED NEURAL PROGENITORS AND USES THEREOF
INVENTOR(S): SABATE, OLIVIER, PARIS, FRANCE
HORELLOU, PHILIPPE, PARIS, FRANCE
BUC-CARON, MARIE-HELENE, PARIS, FRANCE
MALLET, JACQUES, PARIS, FRANCE
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer, S.A. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002006660	A1	20020117
APPLICATION INFO.:	US 1997-810315	A1	19970228 (8)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1996-12635P 19960301 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW,, GARRETT & DUNNER, L.L.P.,
1300 I STREET, N.W., WASHINGTON,, DC, 200053315
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1048

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns human neural progenitor cells containing
introduced genetic material encoding a product of interest, and their
use for the treatment of neurodegenerative diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 39 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:340140 USPATFULL
TITLE: Neural transplantation using proliferated multipotent
neural stem cells and their progeny
INVENTOR(S): Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
PATENT ASSIGNEE(S): NeuroSpheres Holdings Ltd., Calgary, CANADA (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6497872	B1	20021224
APPLICATION INFO.:	US 1995-486313		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation of Ser. No. US 486313 Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned Continuation-in-part of Ser. No. US 726812		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Baker, Anne-Marie
LEGAL REPRESENTATIVE: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
Elrifi, Esq., Ivor R., Karnakis, Esq., Christine V.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4223

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods of transplanting multipotent neural stem
cell progeny to a host by obtaining a population of cells derived from
mammalian neural tissue containing at least one multipotent CNS
multipotent neural stem cell; culturing the neural stem cell in a

multipotent neural stem cell proliferation; inducing proliferation of the multipotent neural stem cell to produce neural stem cell progeny which includes multipotent neural stem cell progeny cells; and transplanting the multipotent neural stem cell progeny to the host. Also provided are methods of transplanting neural stem cell progeny to a host by obtaining an in vitro cell culture containing CNS neural stem cells where one or more cells in the culture (i) proliferates in a culture medium supplemented with one or more mitogens, (ii) retains the capacity for renewed proliferation, and (iii) maintains the multipotential capacity, under suitable culture conditions, to differentiate into neurons, astrocytes, and oligodendrocytes; and transplanting the one or more cells to the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 40 OF 58 USPTAFULL on STN
 ACCESSION NUMBER: 2002:129781 USPTAFULL
 TITLE: Multipotent neural stem cell cDNA libraries
 INVENTOR(S): Weiss, Samuel, Calgary, CANADA
 Reynolds, Brent, Salt Spring, CANADA
 PATENT ASSIGNEE(S): Neurospheres Holdings Ltd., Calgary, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399369	B1	20020604
APPLICATION INFO.:	US 1995-484203		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991 Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993 Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Hayes, Robert C.		
LEGAL REPRESENTATIVE:	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, Elrifi, Esquire, Ivor R., Karnakis, Esq., Christina V.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	3847		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB cDNA libraries may be obtained from neural cell cultures produced by using growth factors to induce the proliferation of multipotent neural stem cells. The libraries may be obtained from both cultured normal and dysfunctional neural cells and from neural cell cultures at various stages of development. This information allows for the identification of the sequence of gene expression during neural development and can be used to reveal the effects of biological agents on gene expression in neural cells. Additionally, nucleic acid derived from dysfunctional tissue can be compared with that of normal tissue to identify genetic material which may be a cause of the dysfunction. This information could then be used in the design of therapies to treat the neurological disorder. A further use of the technology would be in the diagnosis of

stage in development.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 41 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2002:9755 USPATFULL
TITLE: Use of carbon monoxide dependent guanylyl cyclase
modifiers to stimulate neuritogenesis
INVENTOR(S): Glasky, Alvin J., Tustin, CA, United States
Rathbone, Michael P., Hamilton, CANADA
PATENT ASSIGNEE(S): NeoTherapeutics, Inc., Irvine, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6338963	B1	20020115
APPLICATION INFO.:	US 1999-420543		19991019 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-86878, filed on 29 May 1998, now patented, Pat. No. US 6027936 Division of Ser. No. US 1995-488976, filed on 8 Jun 1995, now patented, Pat. No. US 5801184 Continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jun 1994, now patented, Pat. No. US 5447936		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Park, Hankyeol T.		
LEGAL REPRESENTATIVE:	Oppenheimer Wolff & Donnelly LLP, Farber, Esq., Michael B.		
NUMBER OF CLAIMS:	85		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	89 Drawing Figure(s); 53 Drawing Page(s)		
LINE COUNT:	3564		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 42 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2001:220833 USPATFULL
TITLE: Method of determining multiple mRNAs in dying cells
INVENTOR(S): O'Dell, Dianne M., 52 Revere Rd., Apt. 10, Drexel Hill,
PA, United States 19026
Raghupathi, Ramesh, 484 Cassatt Rd., Devon, PA, United
States 19312
McIntosh, Tracy Kahl, 909 Winding La., Wallingford, PA,
United States 19063
Crino, Peter, 34 Hemlock Dr., Blenheim, NJ, United
States 08012
Eberwine, James, 3918 Henry Ave., Philadelphia, PA,
United States 19120

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326146	B1	20011204
APPLICATION INFO.:	US 1999-274900		19990323 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79640P	19980327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fredman, Jeffrey	
ASSISTANT EXAMINER:	Einsmann, Juliet C.	
LEGAL REPRESENTATIVE:	Licata & Tyrrell P.C.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining expression levels of multiple mRNAs in single, dying cells from a selected tissue is provided. The method utilizes terminal deoxynucleotidyl-transferase mediated biotin-dUTP nick end labeling to identify dying cells and measures multiple mRNA expression levels in single, isolated dying cells or portions thereof by amplified ***antisense*** RNA techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 43 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2001:163016 USPATFULL

TITLE: Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents

INVENTOR(S): Weiss, Samuel, Calgary, Canada
Reynolds, Brent, Calgary, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States

PATENT ASSIGNEE(S): Neurospheres Holdings, Ltd., Alberta, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294346	B1	20010925
APPLICATION INFO.:	US 1995-484406		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned, said Ser. No. US 484406 And Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812, said Ser. No. US 338730 Continuation-in-part of Ser. No. US 726812, said Ser. No. US 311099 Continuation-in-part of Ser. No. US 726812, said Ser. No. US 270412 Continuation-in-part of Ser. No. US 726812		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Hayes, Robert C.		
LEGAL REPRESENTATIVE:	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Elrifi, Esq., Ivor R.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	4153		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A culture method for determining the effect of a biological agent on multipotent neural stem cell progeny is provided. In the presence of growth factors, multipotent neural stem cells are induced to proliferate in culture. The multipotent neural stem cells may be obtained from normal neural tissue or from a donor afflicted with a disease such as Alzheimer's Disease, ***Parkinson***'s Disease or Down's Syndrome. At various stages in the differentiation process of the multipotent neural stem cell progeny, the effects of a biological agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid or a drug or pro-drug on cell activity are determined. Additionally, a method of screening the effects of biological agents on a clonal population of neural cells is provided. The technology provides an efficient method for the generation of large numbers of pre- and post-natal neural cells under controlled, defined conditions. The

neural cells at various developmental stages, which can be screened for potential side effects in addition to testing the action and efficacy of different biological agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 44 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2001:102376 USPATFULL
TITLE: Method of treating huntington's disease using HNT
neurons
INVENTOR(S): Freed, Curt R., Denver, CO, United States
Kaddis, Farida G., Lakewood, CO, United States
PATENT ASSIGNEE(S): University Technology Corporation, Boulder, CO, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6254865	B1	20010703
APPLICATION INFO.:	US 1998-99121		19980617 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-49817P	19970617 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Clark, Deborah J. R.	
ASSISTANT EXAMINER:	Wilson, Michael C.	
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2167	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for transplantation of neurons. The methods and compositions of the present invention provide a renewable supply of safe and effective therapeutic transplantable tissue. In particular, the present invention provides methods and compositions for the transplantation of terminally differentiated neurons derived from cell lines for the treatment of Huntington's disease and other neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 45 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2001:51558 USPATFULL
TITLE: Compositions and methods for producing and using
homogenous neuronal cell transplants to treat
neurodegenerative disorders and brain and spinal cord
injuries
INVENTOR(S): Lee, Virginia M. -Y., Philadelphia, PA, United States
Trojanowski, John Q., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Trustees of the University of Pennsylvania,
Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214334	B1	20010410
APPLICATION INFO.:	US 1999-303973		19990503 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-122019, filed on 24 Jul 1998 Continuation of Ser. No. US 1996-640894, filed on 7 Jun 1996, now patented, Pat. No. US 5792900 Continuation of Ser. No. US 1993-150368, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1992-911980, filed on 10 Jul 1992, now abandoned Division of Ser. No. US 1991-780715, filed on 21 Oct 1991, now patented, Pat. No. US 5175103		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Priebe, Scott D.		
ASSISTANT EXAMINER:	Shukla, Ram		
LEGAL REPRESENTATIVE:	Law Office of Jane Massey Licata		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	2211		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

conditions or disorders of the Central Nervous System which comprise implanting stable, homogeneous post-mitotic human neurons into the individual's brain are disclosed. Methods of treating individuals suspected of suffering from injuries, diseases, conditions or disorders characterized by nerve damage which comprise implanting stable, homogeneous post-mitotic human neurons at or near a site of said nerve damage are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 46 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2001:14469 USPATFULL
TITLE: AAV-mediated delivery of DNA to cells of the nervous system
INVENTOR(S): Kaplitt, Michael G., New York, NY, United States
During, Matthew J., Weston, CT, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States (U.S. corporation)
Yale University, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6180613	B1	20010130
APPLICATION INFO.:	US 1995-467044		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-227319, filed on 13 Apr 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chambers, Jasmine		
ASSISTANT EXAMINER:	Martin, Jill D.		
LEGAL REPRESENTATIVE:	Klauber & Jackson		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1725		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB. The invention relates to a method of delivering exogenous DNA to a target cell of the mammalian central nervous system using an adeno-associated virus (AAV)-derived vector. Also included in the invention are the AAV-derived vectors containing exogenous DNA which encodes a protein or proteins which treat nervous system disease, and a method of treating such disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 47 OF 58 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2000:378161 CAPLUS
DOCUMENT NUMBER: 133:27162
TITLE: In vivo genetic modification of growth factor-responsive neural precursor cells
INVENTOR(S): Weiss, Samuel; Reynolds, Brent; Hammang, Joseph P.; Baetge, E. Edward
PATENT ASSIGNEE(S): NeuroSpheres Holdings Ltd., Can.
SOURCE: U.S., 42 pp., Cont.-in-part of U.S. Ser. No. 385,404, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6071889	A	20000606	US 1995-479795	19950607
WO 9301275	A1	19930121	WO 1992-CA283	19920707
W: AU, CA, FI, JP, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9222425	A1	19930211	AU 1992-22425	19920707
AU 665012	B2	19951214		
EP 594669	A1	19940504	EP 1992-914286	19920707
EP 594669	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06509225	T2	19941020	JP 1992-501862	19920707
CA 2113118	C	20020917	CA 1992-2113118	19920707
AT 240389	E	20030515	AT 1992-914286	19920707

EP 1329499	A3	20030903			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC					
WO 9409119	A1	19940428	WO 1993-CA428	19931015	
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9351474	A1	19940509	AU 1993-51474	19931015	
AU 683023	B2	19971030			
EP 664832	A1	19950802	EP 1993-922482	19931015	
EP 664832	B1	20020724			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 08502172	T2	19960312	JP 1994-509473	19931015	
CA 2147162	C	20020430	CA 1993-2147162	19931015	
AT 221117	E	20020815	AT 1993-922482	19931015	
ES 2180547	T3	20030216	ES 1993-922482	19931015	
WO 9410292	A1	19940511	WO 1993-CA456	19931027	
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9453676	A1	19940524	AU 1994-53676	19931027	
EP 669973	A1	19950906	EP 1993-923994	19931027	
EP 669973	B1	20030312			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 08502652	T2	19960326	JP 1993-510503	19931027	
CA 2148138	C	20020108	CA 1993-2148138	19931027	
AT 234353	E	20030315	AT 1993-923994	19931027	
EP 1298202	A2	20030402	EP 2002-18736	19931027	
EP 1298202	A3	20031203			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
ES 2194016	T3	20031116	ES 1993-923994	19931027	
NO 9400056	A	19940303	NO 1994-56	19940106	
CA 2155024	AA	19940804	CA 1994-2155024	19940128	
WO 9416718	A1	19940804	WO 1994-US1053	19940128	
W: AU, CA, FI, JP, KR, NO, US, US, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9460983	A1	19940815	AU 1994-60983	19940128	
AU 687785	B2	19980305			
EP 681477	A1	19951115	EP 1994-907366	19940128	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 08505762	T2	19960625	JP 1994-510446	19940128	
CA 2175992	AA	19950518	CA 1994-2175992	19941108	
WO 9513364	A1	19950518	WO 1994-CA614	19941108	
W: AU, CA, CN, FI, JP, NO, RU, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
EP 728194	A1	19960828	EP 1994-931482	19941108	
EP 728194	B1	20030108			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
CN 1141058	A	19970122	CN 1994-194785	19941108	
JP 09507747	T2	19970812	JP 1994-513499	19941108	
AU 697894	B2	19981022	AU 1994-80561	19941108	
AU 9480561	A1	19950529			
AT 230795	E	20030115	AT 1994-931482	19941108	
ES 2189807	T3	20030716	ES 1994-931482	19941108	
FI 9501677	A	19950407	FI 1995-1677	19950407	
NO 9501378	A	19950407	NO 1995-1378	19950407	
FI 9502022	A	19950427	FI 1995-2022	19950427	
NO 9501617	A	19950427	NO 1995-1617	19950427	
US 5750376	A	19980512	US 1995-483122	19950607	
US 5851832	A	19981222	US 1995-486648	19950607	
FI 9503569	A	19950925	FI 1995-3569	19950726	
NO 9502985	A	19950727	NO 1995-2985	19950727	
CN 1161744	A	19971008	CN 1995-195867	19950922	
EP 1130394	A1	20010905	EP 2001-101622	19950922	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
FI 9601855	A	19960604	FI 1996-1855	19960430	
NO 9601859	A	19960703	NO 1996-1859	19960508	
AU 703729	B2	19990401	AU 1997-49241	19971224	
AU 9749241	A1	19980312			
US 2003082515	A1	20030501	US 2002-199189	20020719	
US 2003095956	A1	20030522	US 2002-199918	20020719	
US 2003109008	A1	20030612	US 2002-199830	20020719	
PRIORITY APPLN. INFO.:			US 1991-726812	A2 19910708	

US 1992-967622	B1 19921028
US 1993-10829	B1 19930129
US 1993-149508	B2 19931109
US 1994-221655	B1 19940401
US 1994-270412	B2 19940705
US 1994-311099	B2 19940923
US 1994-338730	B2 19941114
US 1994-359945	B2 19941220
US 1995-376062	B2 19950120
US 1995-385404	B2 19950207
EP 1992-914286	A3 19920707
WO 1992-CA283	A 19920707
WO 1993-CA428	W 19931015
EP 1993-923994	A3 19931027
WO 1993-CA456	W 19931027
WO 1994-US1053	W 19940128
WO 1994-CA614	W 19941108
US 1994-339730	B2 19941114
US 1994-359345	A 19941220
US 1995-481893	A 19950607
US 1995-486313	A1 19950607
EP 1995-931864	A3 19950922

AB Methods for administering genetic material to dividing neural precursor cell populations in vivo are provided. The genetic material may comprise useful genes for neurotransmitters, growth factors, growth factor receptors, and the like. The genetic material is administered to the brain with one or more growth factors. The growth factors induce proliferation of neural precursor cells, thereby facilitating the incorporation of the genetic material into the cell progeny.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 48 OF 58 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:314557 CAPLUS

DOCUMENT NUMBER: 132:329941

TITLE: Treatment of ***Parkinson*** 's disease with
antisense and triplex oligonucleotides for the
downregulation of ***glutamic*** ***acid***
decarboxylase , glutamate receptors, and GABA
receptors

INVENTOR(S): Schneider, Jay S.

PATENT ASSIGNEE(S): Thomas Jefferson University, USA

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025798	A1	20000511	WO 1999-US26128	19991105
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1135113	A1	20010926	EP 1999-971323	19991105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002528509	T2	20020903	JP 2000-579238	19991105
US 2003060436	A1	20030327	US 1999-435249	19991105

PRIORITY APPLN. INFO.: US 1998-107191P P 19981105
WO 1999-US26128 W 19991105

AB The invention relates to a method of treatment of ***Parkinson*** 's disease, and to the use of ***antisense*** oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the ***Parkinsonian*** brain. ***Antisense*** or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata where the expression of ***glutamic*** ***acid*** ***decarboxylase*** (GAD67, GAD65, or a combination of the two isoforms) is downregulated. The invention also relates to a method of treatment of ***Parkinson*** 's disease where ***antisense*** or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The invention further relates to a method of treatment of ***Parkinson*** 's disease where

motor nuclei for the downregulation of GABA receptors.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 49 OF 58 USPATFULL on STN
ACCESSION NUMBER: 2000:21215 USPATFULL
TITLE: Device and method for encapsulated gene therapy
INVENTOR(S): Hammang, Joseph P., Barrington, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PATENT ASSIGNEE(S): Cytotherapeutics, Inc., Lincoln, RI, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027721		20000222
APPLICATION INFO.:	US 1996-650726		19960520 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Campell, Bruce R.		
ASSISTANT EXAMINER:	Clark, Deborah J. R.		
LEGAL REPRESENTATIVE:	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Elrifi, Ivon R., Prince, John T.		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1,7,16		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1429		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and devices are provided for gene therapy using encapsulated
packaging cell lines to deliver viral particles carrying at least one
heterologous gene encoding at least one biologically active molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 50 OF 58 USPATFULL on STN
ACCESSION NUMBER: 1999:141292 USPATFULL
TITLE: Growth factor-induced proliferation of neural precursor
cells in vivo
INVENTOR(S): Weiss, Samuel, Alberta, Canada
Reynolds, Brent, Alberta, Canada
PATENT ASSIGNEE(S): NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5980885		19991109
APPLICATION INFO.:	US 1995-486307		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 270412 which is a continuation of Ser. No. US 726812, said Ser. No. US 385404 which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812, said Ser. No. US 359945 which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812, said Ser. No. US 376062 which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812, said Ser. No. US 149508 which is a continuation-in-part of Ser. No. US 726812, said Ser. No. US 311099 which is a continuation-in-part of Ser. No. US 726812		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Campbell, Bruce R.		

LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is described for inducing in vivo proliferation of precursor cells located in mammalian neural tissue by administering to the mammal a fibroblast growth factor and at least one additional growth factor selected from the group consisting of epidermal growth factor, transforming growth factor alpha, and amphiregulin. The method can be used to replace damaged or missing neurons and/or glia. Another method is described for transplanting multipotent neural stem cell progeny into a mammal. The method comprises the steps of administering growth factors to a mammal to induce in vivo proliferation of neural precursor cells, removing the precursor cell progeny from the mammal, culturing the removed cells in vitro in the presence of one or more growth factors that induces multipotent neural stem cell proliferation, and implanting the multipotent neural stem cell progeny into the mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 51 OF 58 USPATFULL on STN
ACCESSION NUMBER: 1999:4435 USPATFULL
TITLE: Adeno-associated virus materials and methods
INVENTOR(S): Johnson, Philip R., Gahanna, OH, United States
PATENT ASSIGNEE(S): Children's Hospital, Inc., Columbus, OH, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5858775		19990112
APPLICATION INFO.:	US 1996-709609		19960910 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-254358, filed on 6 Jun 1994, now patented, Pat. No. US 5658785		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Guzo, David		
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 52 OF 58 USPATFULL on STN
ACCESSION NUMBER: 1998:159764 USPATFULL
TITLE: In vitro growth and proliferation of multipotent neural stem cells and their progeny
INVENTOR(S): Weiss, Samuel, Alberta, Canada
Reynolds, Brent, Alberta, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
PATENT ASSIGNEE(S): Neurospheres, Ltd., Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5851832		19981222
APPLICATION INFO.:	US 1995-486648		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned And a continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a		

US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned And Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 726812

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert LLP
NUMBER OF CLAIMS: 80
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4487

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the in vitro proliferation and differentiation of neural stem cells and stem cell progeny comprising the steps of (a) isolating the cells from a mammal, (b) exposing the cells to a culture medium containing a growth factor, (c) inducing the cells to proliferate, and (d) inducing the cells to differentiate is provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 53 OF 58 USPATFULL on STN
ACCESSION NUMBER: 1998:88700 USPATFULL
TITLE: Adeno-associated virus materials and methods
INVENTOR(S): Johnson, Philip R., Gahanna, OH, United States
PATENT ASSIGNEE(S): Children's Hospital, Inc., Columbus, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5786211		19980728
APPLICATION INFO.:	US 1995-475391		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-254358, filed on 6 Jun 1994, now patented, Pat. No. US 5658785		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ketter, James
ASSISTANT EXAMINER: Yucel, Irem
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 911

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 54 OF 58 USPATFULL on STN
ACCESSION NUMBER: 1998:72446 USPATFULL
TITLE: Regulatable retrovirus system for genetic modification of cells
INVENTOR(S): Gage, Fred H., La Jolla, CA, United States
Ray, Jasodhara, San Diego, CA, United States
Hoshimaru, Minoru, Shiga-ken, Japan

CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770414		19980623
APPLICATION INFO.:	US 1996-602203		19960220 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Yucel, Irem		
LEGAL REPRESENTATIVE:	Fish & Richardson, P.C.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1051		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel regulatable retroviral vector in which the v-myc oncogene is driven by a tetracycline-controlled transactivator and a human cytomegalovirus minimal promoter fused to tet operator sequence useful for immortalization of adult neuronal progenitor cells is provided. Regulation of a heterologous Producer cell lines which produce high titers of the recombinant retrovirus are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 55 OF 58 USPATFULL on STN
ACCESSION NUMBER: 1998:51459 USPATFULL
TITLE: In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
INVENTOR(S): Weiss, Samuel, Alberta, Canada
Reynolds, Brent, Alberta, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
PATENT ASSIGNEE(S): NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750376		19980512
APPLICATION INFO.:	US 1995-483122		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1994-359345, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned , said Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned		
DOCUMENT TYPE:	Utility		

PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert, Brezner, David J., Brunelle, Jan P.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1,8,9
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for producing genetically modified neural cells comprises culturing cells derived from embryonic, juvenile, or adult mammalian neural tissue with one or more growth factors that induce multipotent neural stem cells to proliferate and produce multipotent neural stem cell progeny which include more daughter multipotent neural stem cells and undifferentiated progeny that are capable of differentiating into neurons, astrocytes, and oligodendrocytes. The proliferating neural cells can be transfected with exogenous DNA to produce genetically modified neural stem cell progeny. The genetic modification can be for the production of biologically useful proteins such as growth factor products, growth factor receptors, neurotransmitters, neurotransmitter receptors, neuropeptides and neurotransmitter synthesizing genes. The multipotent neural stem cell progeny can be continuously passaged and proliferation reinitiated in the presence of growth factors to result in an unlimited supply of neural cells for transplantation and other purposes. Culture conditions can be provided that induce the genetically modified multipotent neural stem cell progeny to differentiate into neurons, astrocytes, and oligodendrocytes in vitro.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 56 OF 58 USPATFULL on STN
ACCESSION NUMBER: 97:73494 USPATFULL
TITLE: Adeno-associated virus materials and methods
INVENTOR(S): Johnson, Philip R., Gahanna, OH, United States
PATENT ASSIGNEE(S): Children's Hospital, Inc., Columbus, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658785		19970819
APPLICATION INFO.:	US 1994-254358		19940606 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Guzo, David		
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	887		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 57 OF 58 USPATFULL on STN
ACCESSION NUMBER: 97:68345 USPATFULL
TITLE: Gaba.sub.a receptor epsilon subunit
INVENTOR(S): Li, Yi, Gaithersburg, MD, United States
Kirkness, Ewen F., Olney, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5654172		19970805
APPLICATION INFO.:	US 1995-459100		19950602 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fleisher, Mindy		

LEGAL REPRESENTATIVE: Mullins, J. G., Olstein, Elliot M.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 15
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1459

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a human GABA.sub.A epsilon subunit receptor and DNA (RNA) encoding such polypeptides (RNA). Also provided is a procedure for producing such polypeptides by recombinant techniques and agonists and antagonists for such polypeptides. Also provided are methods of using the agonists, for example, to treat anxiety, Huntington's Chorea, muscular spasms and rigidity, and sleep and seizure disorders. Antagonists may be used, for example, to diagnose and treat anxiety, Huntington's Chorea, sleep and seizure disorders, Alzheimer's disease, ***Parkinson***'s disease and overdoses with benzodiazepine and for enhancing cognition and reversing sedation after application of general anesthesia during surgery. Also disclosed are diagnostic methods for detecting mutations in the polynucleotides of the present invention and for detecting levels of the soluble polypeptides in samples derived from a host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 58 OF 58 USPATFULL on STN
ACCESSION NUMBER: 95:34069 USPATFULL
TITLE: Genetic diagnosis of torsion dystonia
INVENTOR(S): Breakefield, Xandra O., Newton, MA, United States
Ozelius, Laurie, Cambridge, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5407821		19950418
APPLICATION INFO.:	US 1991-725083		19910703 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-353432, filed on 18 May 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Parr, Margaret		
ASSISTANT EXAMINER:	Myers, Carla		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2144		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for detecting the presence of a gene for torsion dystonia in a human subject. Furthermore, a haplotype which is associated with torsion dystonia is disclosed. Methods and kits for the detection of torsion dystonia in a subject are additionally provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d all 31

L2 ANSWER 31 OF 58 MEDLINE on STN DUPLICATE 1
AN 2003011859 MEDLINE
DN PubMed ID: 12518298
TI Experimental ***parkinsonism*** is associated with increased pallidal GAD gene expression and is reversed by site-directed ***antisense*** gene therapy.
AU Schneider Jay S; Wade Timothy V
CS Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA..
jay.schneider@mail.tju.edu
SO Movement disorders : official journal of the Movement Disorder Society, (2003 Jan) 18 (1) 32-40.
Journal code: 8610688. ISSN: 0885-3185.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200303
ED Entered STN: 20030109

Entered Medline: 20030319

AB The levels of mRNA encoding the two isoforms of ***glutamic***
 acid ***decarboxylase*** (GAD(65) and GAD(67)) were measured
 throughout the pallidal complex in normal and acutely (i.e., 1 month
 duration) and chronically (i.e., 5 years duration) ***parkinsonian***
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) -treated
 monkeys as well as in monkeys exposed to MPTP but asymptomatic for
 parkinsonism. GAD(65) mRNA labeling was modestly increased in the
 mid/caudal internal globus pallidus (GPi) but not in the external globus
 pallidus (GPe) in ***parkinsonian*** monkeys, compared with normal and
 asymptomatic monkeys. GAD(67) mRNA expression was highly increased in the
 mid/caudal GPi, and modestly increased in the GPe in ***parkinsonian***
 monkeys compared with normal and asymptomatic animals. Infusion of
 GAD(67) ***antisense*** oligodeoxynucleotides bilaterally into the GPi
 resulted in a transient reversal of akinesia and bradykinesia that was not
 produced by infusion of missense oligodeoxynucleotides. These data
 emphasize the role of GAD enzyme (particularly GAD(67)) and GABA in the
 GPi for the expression of ***parkinsonian*** motor signs and suggest
 that selective manipulation of GABAergic neurotransmission in the GPi may
 have therapeutic potential for treating ***parkinsonism***.
 Copyright 2002 Movement Disorder Society

CT Check Tags: Female; Male; Support, Non-U.S. Gov't
 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
 Animals
 *Gene Therapy: MT, methods
 *Globus Pallidus: PA, pathology
 *Glutamate Decarboxylase: GE, genetics
 *Isoenzymes: GE, genetics
 Macaca fascicularis
 *Mutagenesis, Site-Directed: GE, genetics
 ****Oligodeoxyribonucleotides, Antisense: PD, pharmacology***
 ****Parkinsonian Disorders: GE, genetics***
 *** Parkinsonian Disorders: PA, pathology***
 *** Parkinsonian Disorders: TH, therapy***
 RNA, Messenger: GE, genetics
 Saimiri

RN 28289-54-5 (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
 CN 0 (Isoenzymes); 0 (Oligodeoxyribonucleotides, ***Antisense***); 0
 (RNA, Messenger); EC 4.1.1.- (GAD65 enzyme); EC 4.1.1.- (GAD67 enzyme); EC
 4.1.1.15 (Glutamate Decarboxylase)

=>

=>

Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	129.65	129.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.39	-1.39

SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 11:01:31 ON 03 MAR 2004